In 112 patients with third-line metastatic colorectal cancer, etrumadenant, zimberelimab, FOLFOX and bevacizumab improved median PFS vs regorafenib (6.2 vs 2.1 months; HR 0.27); grade 3 or higher adverse events were more common (82% vs 49%).
RCTn = 112
Cecchini et al. The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer